<br>        Inclusion Criteria:<br><br>          -  Age: from 65 to 85 years<br><br>          -  Body Mass Index: 22-30 kg/m2<br><br>          -  ECOG Performance status: WHO performance score 0 to 2<br><br>          -  Absence of known diseases and/or abnormalities of haematological parameters<br>             (haematological, inflammatory, metabolic, hepatic and renal diseases)<br><br>          -  The subjects must be able to comply with management of nutraceutical products and<br>             with scheduled follow-up<br><br>          -  The subjects must be able to use the computer and to access to the web, by themselves<br>             or with the help of a caregiver<br><br>        Exclusion Criteria:<br><br>          -  History of significant neurologic or psychiatric disorders including dementia,<br>             seizures, bipolar disorder<br><br>          -  Geriatric anorexia [less than 2 full meals per day and /or less than one serving of<br>             dairy products (milk, cheese, yogurt) per day or two or more servings of legumes or<br>             eggs per week or one serving of meat, fish or poultry every day]<br><br>          -  Weight loss > 5% in the last month<br><br>          -  Previous antibiotic treatment within 4 months<br><br>          -  Active infection requiring per OS or IV antibiotics, including active tuberculosis,<br>             known and declared HIV, HCV<br><br>          -  Constipation and/or abdominal pain/discomfort that require dietary supplements or<br>             medical therapy<br><br>          -  Gastric disease that requires medical therapy (e.g. gastric secretion inhibitory<br>             drugs)<br><br>          -  Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis,<br>             diverticulosis, diverticulitis)<br><br>          -  Diabetes mellitus<br><br>          -  Dislipidemia and/or any metabolic disease that requires medical or dietetic treatment<br><br>          -  Myocardial infarction within 6 months prior to study entry, congestive heart disease,<br>             uncontrolled cardiac insufficiency, and any current grade 3 or 4 cardio-vascular<br>             disorder despite treatment<br><br>          -  Current history of neoplasm except for curatively treated non melanoma skin cancer or<br>             in situ carcinoma of the cervix and except for other cancer curatively treated and<br>             with no evidence of disease for at least 5 years<br><br>          -  Other sever underlying medical conditions, which could impair the ability of the<br>             patient to participate in the study<br><br>          -  Chronic anti-inflammatory therapy with FANS or previous therapy within 20 days from<br>             the beginning of the study. The occasional use of anti-inflammatory therapy is not an<br>             exclusion criteria, but the use is not allowed within 3 days before the analysis and<br>             for more than 8 days/2 months during the study<br><br>          -  Previous (within 15 days) or concomitant treatment that modifies intestinal<br>             absorption (e.g. metformin, acarbose in diabetic treatment…)<br><br>          -  Probiotics, prebiotics or symbiotics (yogurt or another functional foods) intake in<br>             the last 3 weeks<br><br>          -  Use of food supplements or functional foods such as probiotics, prebiotics,<br>             symbiotics, vitamins and minerals different than whose established in this study, is<br>             not allowed during the study period or previously within 1 week (except for vitamin<br>             D, calcium, vitamin B12)<br><br>          -  Total parenteral nutrition within 4 months<br><br>          -  History of allergy to one of the excipients present in the products under evaluation<br><br>          -  Concomitant or within 4 week period administration of any experimental drug, food<br>             supplements or nutraceuticals under investigation<br><br>          -  Subjects clearly intending to withdraw from the study if not randomised in a given<br>             arm, or subjects who cannot be regularly followed up for psychological, social,<br>             familial or geographic reasons<br><br>          -  Subjects with expected non-compliance to protocol guidelines<br>